BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BOSTON SCIENTIFIC CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $66.44B
- P/E (TTM)
- 18.2
- Dividend yield
- –
BOSTON SCIENTIFIC CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3.62B | $3.50B | $3.48B | $3.34B | $3.35B | $3.09B | $2.94B | $2.73B | $2.64B | $2.45B | $2.29B | $2.19B | 66.6% | +8.3% |
| MedSurg | $1.82B | $1.70B | $1.81B | $1.72B | $1.72B | $1.58B | $1.62B | $1.48B | $1.48B | $1.41B | $1.44B | $1.34B | 33.4% | +5.9% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.33B | $1.24B | – | $686.00M | $1.18B | $1.12B | $668.00M | $661.00M | $665.00M | $652.00M | $614.00M | $583.00M | 24.5% | +13.2% |
| Electrophysiology | $916.00M | $905.00M | $890.00M | $865.00M | $840.00M | $730.00M | $649.00M | $527.00M | $428.00M | $300.00M | $240.00M | $190.00M | 16.8% | +9.0% |
| Endoscopy | $793.00M | $736.00M | $759.00M | $747.00M | $737.00M | $673.00M | $691.00M | $678.00M | $676.00M | $642.00M | $646.00M | $629.00M | 14.6% | +7.6% |
| Urology | $684.00M | $646.00M | $717.00M | $682.00M | $676.00M | $633.00M | $630.00M | $532.00M | $525.00M | $513.00M | $527.00M | $483.00M | 12.6% | +1.2% |
| Cardiac Rhythm Management | $585.00M | $578.00M | $586.00M | $578.00M | $590.00M | $578.00M | $566.00M | $561.00M | $576.00M | $575.00M | $553.00M | $552.00M | 10.7% | -0.8% |
| Watchman | $507.00M | $506.00M | $535.00M | $512.00M | $486.00M | $425.00M | $413.00M | $380.00M | $379.00M | $344.00M | $344.00M | $323.00M | 9.3% | +4.3% |
| Neuromodulation | $341.00M | $318.00M | $333.00M | $293.00M | $303.00M | $271.00M | $299.00M | $268.00M | $282.00M | $256.00M | $268.00M | $229.00M | 6.3% | +12.5% |
| Interventional Oncology & Embolization | $283.00M | $268.00M | – | – | $251.00M | $228.00M | – | – | – | – | – | – | 5.2% | +12.7% |
| Peripheral Interventions [Member] | – | – | – | $702.00M | $698.00M | $656.00M | $645.00M | $602.00M | $590.00M | $573.00M | $533.00M | $538.00M | – | – |
| Cardiology [Member] | – | – | – | $2.64B | $2.65B | $2.43B | $2.30B | $2.13B | $2.05B | $1.87B | $1.75B | $1.65B | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.43B | $3.28B | $3.39B | $3.29B | $3.22B | $2.96B | $2.89B | $2.59B | $2.47B | $2.26B | $2.21B | $2.10B | 63.0% | +6.3% |
| Int'l | $2.02B | $1.92B | $1.90B | $1.77B | $1.84B | $1.70B | $1.67B | $1.62B | $1.65B | $1.60B | $1.51B | $1.43B | 37.1% | +9.8% |
| Emerging Markets | – | – | $771.00M | $765.00M | $758.00M | $690.00M | $668.00M | $684.00M | $680.00M | $648.00M | $595.00M | $594.00M | – | – |
From the segment and revenue-disaggregation notes of Boston Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.